Eleftherios P Mamounas

Summary

Affiliation: Northeastern Ohio Universities College of Medicine
Country: USA

Publications

  1. pmc Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
    Sommer R Gunia
    Department of Surgery, Affinity Medical Center, Massillon, OH 44646, USA
    Case Rep Surg 2012:454273. 2012
  2. pmc Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW, Canton, OH 44710, USA
    J Clin Oncol 30:3960-6. 2012
  3. pmc Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Departmentof Biostatistics, Graduate School of Public Health, University of Pittsburgh, USA
    J Clin Oncol 28:1677-83. 2010
  4. ncbi Sentinel lymph node biopsy after neoadjuvant systemic therapy
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, 4209 State Route 44, Rootstown, Ohio 44272, USA
    Surg Clin North Am 83:931-42. 2003
  5. ncbi Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
    Clin Breast Cancer 4:S121-6. 2004
  6. ncbi Can we approach zero relapse in breast cancer?
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, Aultman Cancer Center, 2600 6th Street SW, Canton, Ohio 44710, USA
    Oncologist 10:9-17. 2005
  7. doi Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
    J Clin Oncol 26:1965-71. 2008
  8. ncbi Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Clin Oncol 23:2694-702. 2005
  9. doi Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, Aultman Cancer Center, 2600 6th Street SW, Canton, Ohio 44710, USA
    Ann Surg Oncol 15:691-703. 2008
  10. ncbi Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 23:3686-96. 2005

Detail Information

Publications62

  1. pmc Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
    Sommer R Gunia
    Department of Surgery, Affinity Medical Center, Massillon, OH 44646, USA
    Case Rep Surg 2012:454273. 2012
    ..Documented eradication of DCIS has not been reported following NC when malignant-appearing calcifications persist and this observation may have important clinical implications regarding surgical management...
  2. pmc Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW, Canton, OH 44710, USA
    J Clin Oncol 30:3960-6. 2012
    ..The limited information on predictors of locoregional recurrence (LRR) after neoadjuvant chemotherapy (NC) has resulted in controversy about the optimal use of adjuvant radiotherapy and the timing of sentinel lymph node biopsy...
  3. pmc Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Departmentof Biostatistics, Graduate School of Public Health, University of Pittsburgh, USA
    J Clin Oncol 28:1677-83. 2010
    ....
  4. ncbi Sentinel lymph node biopsy after neoadjuvant systemic therapy
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, 4209 State Route 44, Rootstown, Ohio 44272, USA
    Surg Clin North Am 83:931-42. 2003
    ..This observation has the potential to expand the utility of neoadjuvant chemotherapy in patients with operable breast cancer...
  5. ncbi Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
    Clin Breast Cancer 4:S121-6. 2004
    ..These trials will be important in establishing a role for this agent in the adjuvant setting and will hopefully lead to the development of more effective adjuvant chemotherapy regimens in the future...
  6. ncbi Can we approach zero relapse in breast cancer?
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, Aultman Cancer Center, 2600 6th Street SW, Canton, Ohio 44710, USA
    Oncologist 10:9-17. 2005
    ..These recent developments have demonstrated that the notion of approaching zero relapse in breast cancer patients is now within our reach...
  7. doi Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
    J Clin Oncol 26:1965-71. 2008
    ....
  8. ncbi Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Clin Oncol 23:2694-702. 2005
    ..Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy...
  9. doi Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, Aultman Cancer Center, 2600 6th Street SW, Canton, Ohio 44710, USA
    Ann Surg Oncol 15:691-703. 2008
    ..The availability of the AIs for effective and well-tolerated neoadjuvant and/or adjuvant endocrine therapy represents an important advance in breast cancer treatment, and surgeons should be familiar with these new therapeutic options...
  10. ncbi Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 23:3686-96. 2005
    ....
  11. ncbi Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer
    E P Mamounas
    Department of Surgery, Northeastern Ohio Universities College of Medicine, Medical Director, Aultman Cancer Center, Canton, OH 44710, USA
    Clin Breast Cancer 2:S20-30. 2001
    ..Similarly, novel targeted therapies such as trastuzumab and bisphosphonates are currently being evaluated in adjuvant studies..
  12. pmc NSABP breast cancer clinical trials: recent results and future directions
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, Ohio 44710, USA
    Clin Med Res 1:309-26. 2003
    ..Results from these ongoing and recently completed trials could improve outcomes and quality of life for patients with early-stage breast cancer...
  13. pmc Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Washington Cancer Institute at Washington Hospital Center, Washington, DC 20010, USA
    N Engl J Med 362:2053-65. 2010
    ..The effectiveness of concurrent versus sequential regimens is not known...
  14. pmc Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial
    Patricia A Ganz
    National Surgical Adjuvant Breast and Bowel Project Operations Center NSABP, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 29:1110-6. 2011
    ..The National Surgical Adjuvant Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies to compare treatments on these outcomes...
  15. ncbi Is sentinel node biopsy necessary in conservatively treated DCIS?
    Thomas B Julian
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, Pennsylvania, USA
    Ann Surg Oncol 14:2202-8. 2007
    ..Its use in patients with DCIS versus local excision (LE), observation, and/or breast irradiation remains in question...
  16. pmc Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
    David N Krag
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    Lancet Oncol 11:927-33. 2010
    ....
  17. ncbi Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
    ..Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines...
  18. doi Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
    Andre Robidoux
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA Centre Hospitalier de l Université de Montréal, Montreal, QC, Canada Electronic address
    Lancet Oncol 14:1183-92. 2013
    ....
  19. doi Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Breast Cancer Res Treat 113:315-20. 2009
    ..These results can be used to inform premenopausal women about the risk and time course of amenorrhea associated with this common adjuvant therapy regimen, along with the effects on symptoms and QOL...
  20. doi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS...
  21. doi Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Gong Tang
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, and Pathology Division, Pittsburgh, PA, USA
    Breast Cancer Res Treat 127:133-42. 2011
    ..219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit...
  22. pmc Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistics Center, Pittsburgh, PA, USA
    Ann Surg Oncol 15:3227-31. 2008
    ....
  23. pmc Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer
    Stewart J Anderson
    Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
    J Clin Oncol 27:2466-73. 2009
    ..Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease...
  24. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  25. ncbi NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-fr
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
    Clin Breast Cancer 7:416-21. 2006
  26. ncbi The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project
    D Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
    World J Surg 30:1138-46. 2006
    ....
  27. ncbi Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 3:333-40. 2002
    ..6 months (95% CI, 26.6-39.4 months). The administration of ATC with primary ciprofloxacin and secondary colony-stimulating factor prophylaxis is feasible and active. Its value in the adjuvant setting is currently under investigation...
  28. ncbi Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
    J Clin Oncol 20:4141-9. 2002
    ....
  29. ncbi Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel
    Alphonse G Taghian
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Graduate School of Public Health, University of Pittsburgh, PA, USA
    J Clin Oncol 24:3927-32. 2006
    ..In this study, we assess patterns of locoregional failure (LRF) in LN-negative patients who underwent mastectomy, either with or without adjuvant chemotherapy or hormonal therapy and without postmastectomy radiation therapy (PMRT)...
  30. pmc Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal gr
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, East Commons Professional Building, Four Allegheny Center, 5th Floor, Pittsburgh, PA 15212, USA
    J Clin Oncol 30:3792-9. 2012
    ..Given the demonstrated efficacy of trastuzumab, ongoing assessment of cardiac safety and identification of risk factors for CD are important for optimal patient care...
  31. ncbi Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Clin Oncol 24:2019-27. 2006
    ..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)...
  32. ncbi Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 24:2028-37. 2006
    ..Locoregional failure after breast-conserving surgery is associated with increased risk of distant disease and death. The magnitude of this risk in patients receiving chemotherapy has not been adequately characterized...
  33. pmc The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project
    D Lawrence Wickerham
    NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Semin Oncol 35:522-9. 2008
    ....
  34. pmc Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors
    Gong Tang
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers
    J Clin Oncol 29:4365-72. 2011
    ..Pathologic and clinical factors such as tumor size, grade, and patient age also provide independent prognostic utility. We developed a formal integration of these measures and evaluated its prognostic and predictive value...
  35. doi Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer
    Thomas B Julian
    Allegheny Breast Care Center, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, USA
    J Clin Oncol 26:3338-45. 2008
    ..We present the results from a large, prospective evaluation of the first rapid molecular SLN test, the Breast Lymph Node (BLN) Assay...
  36. pmc Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31
    Katherine L Pogue-Geile
    Affiliations of authors National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA J HJ, HB, PR, LF, EHR, SMS, EPM, DLW, CEG, Jr, JPC, NW, SP Division of Pathology, NSABP KLP G, CK, NT, PGG, DF, YT, OLB, AL, S IK, MLR, MYR, NLB, S RK, ZDH Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA J HJ, HB, JPC PhenoPath Laboratories, PLLC, Seattle, Germany
    J Natl Cancer Inst 105:1782-8. 2013
    ..This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31...
  37. ncbi Neoadjuvant chemotherapy for operable breast cancer: is this the future?
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
    Clin Breast Cancer 4:S10-9. 2003
    ....
  38. ncbi Evaluation of appropriate short-term mammographic surveillance in patients who undergo breast-conserving Surgery (BCS)
    Sommer R Gunia
    Affinity Medical Center, Massillon, OH, USA
    Ann Surg Oncol 19:3139-43. 2012
    ..Currently there is no consensus on the optimal interval for imaging evaluation of patients following BCS...
  39. doi Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43
    Kalliopi P Siziopikou
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    Breast Cancer Res Treat 142:415-21. 2013
    ..9 %, lower than the previously reported rate. No trastuzumab-related safety signals have been observed. Interest in this trial has been robust. ..
  40. doi Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
    Alexander H G Paterson
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Lancet Oncol 13:734-42. 2012
    ..The National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-34 aims to ascertain whether oral clodronate can improve outcomes in women with primary breast cancer...
  41. ncbi Antiaromatase agents after adjuvant tamoxifen: rationale and clinical implications
    E P Mamounas
    Aultman Cancer Center, Canton, OH 44710, USA
    Clin Breast Cancer 1:S22-7. 2000
    ....
  42. doi Drug development: neoadjuvant opportunities in breast cancer
    Priya Rastogi
    From the University of Pittsburgh Cancer Institute, Pittsburgh, PA University of Texas Southwestern Medical Center, Dallas, TX MD Anderson Cancer Center Orlando, Orlando, FL University of Pennsylvania, Philadelphia, PA
    Am Soc Clin Oncol Educ Book 33:73-9. 2013
    ..New agents are being evaluated in patients with high-risk residual disease following standard treatment regimens. ..
  43. ncbi Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling
    Eleftherios P Mamounas
    Northeastern Ohio Universities College of Medicine, Aultman Cancer Center, Canton, OH 44710, USA
    Clin Adv Hematol Oncol 6:1-8. 2008
    ..In addition, sample case studies offer tangible examples of the practical application of Oncotype DX...
  44. ncbi Long-term clinical and radiologic results with autologous fat transplantation for breast augmentation: case reports and review of the literature
    Srinivas R Pulagam
    Aultman Cancer Center, Canton, Ohio 44710, USA
    Breast J 12:63-5. 2006
    ..We also review the existing literature on the subject as it relates to long-term effects and complications...
  45. ncbi Preoperative (neoadjuvant) chemotherapy in patients with breast cancer
    E P Mamounas
    Department of Surgery, Case Western Reserve University and Aultman Cancer Center, Canton, OH 44710, USA
    Semin Oncol 28:389-99. 2001
    ..The potential advantages and disadvantages of each approach, as well as surgical considerations and current and future directions in the use of preoperative chemotherapy, are also discussed...
  46. ncbi Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Scientific Director s Office, Pittsburgh, PA 15261, USA
    J Clin Oncol 14:1982-92. 1996
    ....
  47. ncbi Combined anthracycline-taxane regimens in the adjuvant setting
    E P Mamounas
    Aultman Cancer Center, Canton, OH 44202, USA
    Semin Oncol 28:24-31. 2001
    ..The outcome of these trials is greatly anticipated because they have the potential of changing the current standards of care in the adjuvant treatment of patients with breast cancer...
  48. ncbi Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience
    A Soran
    NSABP Biostatistical Center, Pittsburgh, PA 15213, USA
    Clin Trials 3:478-85. 2006
    ....
  49. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002
    Eric P Winer
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3317-27. 2002
    ..POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane...
  50. ncbi Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials
    James J Dignam
    Department of Health Studies, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    J Clin Oncol 21:413-20. 2003
    ..The randomized trial setting enhances uniformity in disease stage and treatment plan among all participants...
  51. ncbi American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting
    Eric P Winer
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 21:2597-9. 2003
  52. ncbi A roundtable discussion of aromatase inhibitors as therapy for breast cancer
    D Craig Allred
    Baylor College of Medicine, Houston, Texas, USA
    Breast J 9:213-22. 2003
    ..Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease...
  53. ncbi Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
    David N Krag
    University of Vermont, College of Medicine, Burlington, VT 05405 0068, USA
    Lancet Oncol 8:881-8. 2007
    ..The aim of this paper is to report the technical success and accuracy of SLN resection plus ALND versus SLN resection alone...
  54. doi Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Blvd, Unit 1202, Houston, TX 77030, USA
    J Clin Oncol 26:791-7. 2008
    ..To review the state of the science with respect to diagnostic imaging and locoregional therapy for patients with breast cancer receiving preoperative chemotherapy...
  55. ncbi Continuing evolution in breast cancer surgical management
    Eleftherios P Mamounas
    J Clin Oncol 23:1603-6. 2005
  56. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 23:619-29. 2005
    ..To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors...
  57. ncbi Tailoring loco-regional therapy with neoadjuvant chemotherapy: another step in the right direction
    Eleftherios P Mamounas
    Ann Surg Oncol 11:888-91. 2004
  58. pmc Accelerated partial breast irradiation after conservative surgery for breast cancer
    Henry M Kuerer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 239:338-51. 2004
    ..To critically review the theoretical and actual risks and benefits of accelerated partial breast irradiation (APBI) after breast-conserving surgery...
  59. ncbi Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer
    Sandra M Swain
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 96:516-23. 2004
    ....
  60. ncbi The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    Virginia Commonwealth University, Medical College of Virginia School of Medicine, Richmond, VA, USA
    J Clin Oncol 21:4165-74. 2003
    ....
  61. ncbi Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer
    James J Dignam
    Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 95:1467-76. 2003
    ..We evaluated the association of obesity with outcomes and with tamoxifen efficacy in women with early-stage, hormone-responsive breast cancer participating in a multicenter cancer cooperative group clinical trial...
  62. ncbi Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project
    Lisa A Newman
    Breast Care Center, University of Michigan, 1500 East Medical Center Drive, 3308 CGC, Ann Arbor, MI 48109 0932, USA
    Surg Clin North Am 87:279-305, vii. 2007
    ..This article focuses on presenting the study designs, aims, and primary endpoint results of these studies...